Insulin injection

This product is a hypoglycemic drug. The main effect of insulin is to lower blood sugar, and it also affects protein and fat metabolism, including the following effects. 1. Inhibits liver glycogenolysis and gluconeogenesis, reducing liver output of glucose. 2. Promotes liver uptake of glucose and synthesis of liver glycogen. 3. Promotes muscle and adipose tissue to take in glucose and amino acids, promotes protein and fat synthesis and storage. 4. Promotes the liver to produce very low density lipoprotein and activate lipoprotein lipase, promoting the decomposition of very low density lipoprotein. 5. Inhibits the decomposition of fat and protein in fat and muscle, inhibits the production of ketone bodies and promotes the use of ketone bodies by surrounding tissues.

The main ingredients of this product are: sterile aqueous solution of insulin (porcine or bovine), which can contain 1.4-1.8g of glycerol and 0.25g of phenol per 100ml.

This drug is a sterile hydrochloric acid solution of insulin, which is clear and colorless or almost colorless in appearance. Each 1 mL contains 20, 40 or 80 international units of insulin, and is added with 0.2% phenol as a preservative and an appropriate amount of glycerol. This drug is extracted from fresh pancreas.

1. Type 1 diabetes. 2. Type 2 diabetes with severe stress such as severe infection, trauma, major surgery, and combined cardiovascular and cerebrovascular complications, kidney or retinal diseases. 3. Diabetic ketoacidosis, hyperglycemia and non-ketotic hyperosmolar coma. 4. Long-term type 2 diabetes with low plasma insulin levels, unsatisfactory control after reasonable diet, physical activity and oral hypoglycemic drugs, and type 2 diabetes with contraindications to oral hypoglycemic drugs, such as pregnancy and breastfeeding. 5. Adult or elderly diabetic patients with acute onset, significant weight loss and obvious emaciation. 6. Gestational diabetes. 7. Diabetes secondary to severe pancreatic disease. 8. For severe malnutrition, emaciation, intractable vomiting during pregnancy, and early stage of cirrhosis, glucose and small doses of insulin can be given by intravenous drip at the same time to promote the use of glucose by tissues.

1 Subcutaneous injections are generally given three times a day, 15 to 30 minutes before meals, and a small amount can be added before bedtime if necessary. The dosage starts with a small dose (2 to 4 units each time depending on weight and other factors) and is gradually adjusted according to the condition, blood sugar, and urine sugar. The total amount of insulin required for patients with type 1 diabetes is mostly between 0.5 and 1 unit per kilogram of body weight, which is adjusted according to the results of blood sugar monitoring. The total amount required for patients with type 2 diabetes varies greatly. In the absence of acute complications, sensitive people only need 5 to 10 units per day, generally about 20 units. Obese people with poor insulin sensitivity may require significantly more. In the case of acute complications (infection, trauma, surgery, etc.), patients with type 1 and type 2 diabetes should be injected once every 4 to 6 hours, and the dosage should be adjusted according to changes in the condition and blood sugar monitoring results. 2 Intravenous injection is mainly used for the treatment of diabetic ketoacidosis and hyperglycemic hyperosmolar coma. It can be continuously dripped intravenously at 4 to 6 units per hour for adults and 0.1 unit/kg per hour for children, and the dose can be adjusted according to blood sugar changes; it can also be injected intravenously for the first time with 10 units plus intramuscular injection of 4 to 6 units, and adjusted according to blood sugar changes. For patients with more serious conditions, 10 units can be injected intravenously first, followed by intravenous drip. When blood sugar drops below 13.9mmol/L (250mg/ml), the insulin dose and injection frequency will be reduced accordingly. While using insulin, fluids should also be replenished to correct electrolyte disorders and acidosis and pay attention to the body's need for calories. Diabetic patients who cannot eat should drip insulin while receiving intravenous infusion of glucose solution.

Allergic reaction, redness, swelling, itching, urticaria, and angioedema at the injection site. 1 Hypoglycemia reaction, sweating, palpitations, fatigue, and in severe cases, impaired consciousness, ataxia, tachycardia, and even coma. 2 Insulin resistance, daily dose must be more than 200 units. 3 Fat atrophy and fat hyperplasia at the injection site. 4 Refractive disorders.

Contraindicated in patients allergic to insulin.

1. Glucocorticoids, adrenocorticotropic hormone, glucagon, estrogen, oral contraceptives, epinephrine, phenytoin sodium, thiazide diuretics, thyroxine, etc. can increase blood sugar concentration to varying degrees. When used together, the dose of these drugs or insulin should be adjusted. 2. Oral hypoglycemic drugs and insulin have a synergistic hypoglycemic effect. 3. Anticoagulants, salicylates, sulfonamides and anti-tumor drugs such as methotrexate can compete with insulin and bind to plasma proteins, thereby increasing the level of free insulin in the blood. Non-steroidal anti-inflammatory analgesics can enhance the hypoglycemic effect of insulin. 4. b-receptor blockers such as propranolol can prevent the reaction of adrenaline to increase blood sugar and interfere with the body's function of regulating blood sugar. When used together with insulin, it can increase the risk of hypoglycemia, and can mask the symptoms of hypoglycemia and prolong the time of hypoglycemia. When used together, the dose of insulin should be adjusted. 5. Moderate to large amounts of alcohol can enhance the hypoglycemic effect caused by insulin, which can cause severe and persistent hypoglycemia, which is more likely to occur when fasting or when there is less glycogen in the liver. 6 Chloroquine, quinidine, quinine, etc. can delay the degradation of insulin, increase the insulin concentration in the blood and thus enhance its hypoglycemic effect. 7 Blood sugar-raising drugs such as certain calcium channel blockers, clonidine, danazol, diazoxide, growth hormone, heparin, H2 receptor antagonists, marijuana, morphine, nicotine, sulfinpyrazone, etc. can change sugar metabolism and increase blood sugar. Therefore, the dosage of insulin should be appropriately increased when used in combination with the above drugs. 8 Angiotensin enzyme inhibitors, bromocriptine, clofibrate, ketoconazole, lithium, mebendazole, pyridoxine, theophylline, etc. can directly or indirectly reduce blood sugar in different ways. When insulin is used in combination with the above drugs, the dosage should be appropriately reduced. 9 Octreotide can inhibit the secretion of growth hormone, glucagon and insulin, and delay gastric emptying and slow gastrointestinal motility, causing delayed food absorption, thereby reducing postprandial hyperglycemia. When starting to use octreotide, the insulin dosage should be appropriately reduced and then adjusted according to blood sugar. 10 Smoking can antagonize the blood sugar-lowering effect of insulin by releasing catecholamines. Smoking can also reduce the skin's absorption of insulin. Therefore, when smokers who are currently taking insulin suddenly quit smoking, they should observe changes in blood sugar and consider whether they need to reduce the amount of insulin appropriately.

This medicine should be stored above 0℃ and below 15℃, avoid freezing and keep away from light.

10ml:400 units

Wuhan Changlian Laifu Pharmaceutical Co., Ltd.

• Founded in:

  2004-05-19

• Address:

  No. 12, Jiang'an Road, Jiang'an District, Wuhan

• Tax NO.:

  91420000761225378J

• Registered Funds:

  117.7372 million yuan

• Website:

  Log in to view

• Email:

  Log in to view